Inclusion Criteria:

          1. Patients with pseudomyxoma peritonei or peritoneal carcinomatosis of digestive origin
             or primary peritoneum: appendiceal mucinous tumor or adenocarcinoma (including goblet
             cell cancer and signet ring cell cancer), colorectal cancer, gastric cancer, primary
             peritoneal adenocarcinoma, and mesothelioma, regardless of the number of prior
             treatment lines. Clinical diagnosis is required prior to surgery and pathologic
             diagnosis of peritoneal surface disease must be confirmed from surgical pathology.

          2. Age ≥18 years

          3. Eastern Cooperative Oncology Group performance status of 0 or 1

          4. Patients must be candidates for grossly complete cytoreduction surgery with life
             expectancy greater than 3 months

          5. Patients must have normal organ and marrow function as defined below:

               -  absolute neutrophil count >1,500/microliter (mcL) and white blood cells >
                  4000/mm3

               -  platelets >75,000/microliters

               -  total bilirubin < 3x upper limit normal for institutional limits

               -  aspartate aminotransferase (AST) / Alanine aminotransferase (ALT) <2.5x
                  institutional upper limit of normal

               -  creatinine within normal institutional limits

          6. Documentation of measurable disease by radiographic peritoneal carcinomatosis index
             (PCI) score and RECIST criteria with preoperative measurements taken within 4 weeks of
             study entry. Presence of measurable disease is required for entry into this study.

          7. Women of child-bearing potential and men must agree to use adequate contraception
             (barrier or hormonal plus barrier method of birth control; abstinence) prior to study
             entry and for the duration of study participation (at least first 6 months). Should a
             woman become pregnant or suspect she is pregnant while participating in this study,
             she should inform her treating physician immediately.

          8. Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          1. Patients with peritoneal disease considered to be unresectable according to
             preoperative clinical criteria.

          2. Patients who undergo debulking for palliation with persistence of gross residual
             disease (complete of cytoreduction score 3, CC=3) will be ineligible for the study.

          3. Large burden visceral metastases or extra-abdominal metastases.

          4. Patients who have had radiotherapy within 4 weeks prior to entering the study or those
             who have not recovered from adverse events due to agents administered more than 4
             weeks earlier. There is no limit on the number of prior lines of chemotherapy.

          5. Patients may not be receiving any other investigational agents.

          6. History of allergic reactions to nal-IRI or irinotecan.

        7 Uncontrolled ongoing illness including, but not limited to, ongoing or active infection,
        symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or
        psychiatric illness/social situations that would limit compliance with study requirements.

        8 Pregnant or breast-feeding women are excluded from this study.

        9 HIV-positive patients on combination antiretroviral therapy are ineligible because of the
        potential for pharmacokinetic interactions. In addition, these patients are at increased
        risk of lethal infections when treated with marrow-suppressive therapy.